Monte Rosa Therapeutics, Inc. (GLUE) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -37.37M | -43.01M | 100.43M | -34.72M | -45.49M | 128.92M | -20.99M | -27.77M | -38.16M | 29.63M | -24.71M | -25.32M |
| Operating CF Margin % | -887.62% | -1546.71% | 786.56% | -149.69% | -53.56% | 212.58% | -227.8% | -591.42% | -3586.94% | - | - | - |
| Operating CF Growth % | 17.86% | -133.36% | 578.37% | -25.04% | -19.2% | 335.05% | 15.02% | -9.65% | -63.06% | 223.68% | -19.93% | -23.53% |
| Net Income | -44.5M | -46.13M | -27.08M | -12.29M | 46.88M | 13.44M | -23.86M | -30.31M | -31.97M | -33.25M | -34.88M | -35.18M |
| Depreciation & Amortization | 2.03M | 2.09M | 2.73M | 2.13M | 2.05M | 2.06M | 2.68M | 2.06M | 1.9M | 1.85M | 1.83M | 1.39M |
| Stock-Based Compensation | 0 | 4.31M | 4.36M | 4.89M | 5.3M | 4.47M | 4.28M | 4.5M | 4.87M | 4.07M | 4.47M | 4.15M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2M | 0 | 0 |
| Other Non-Cash Items | 4.96M | 87K | 117.99M | -737K | -1.09M | -696K | -13.26M | -1.09M | -69K | 1.26M | -497K | -1.44M |
| Working Capital Changes | 141K | -3.36M | 2.42M | -28.71M | -98.64M | 109.65M | 9.16M | -2.92M | -12.9M | 57.7M | 4.37M | 5.75M |
| Change in Receivables | 6.99M | -2.21M | -4.79M | -961K | -1.24M | 422K | 8.91M | -9.33M | -10K | -336 | 375K | -195K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 336 | 0 | 0 |
| Change in Payables | 4.38M | -10.61M | 0 | -1.1M | -10.87M | 13.31M | 0 | 394K | -5.07M | 5.77M | 686K | -1M |
| Cash from Investing | -261M | -65.07M | 38.14M | 25.32M | -100.23M | -30.9M | 37.75M | -61.16M | 9.85M | 14.3M | 35.63M | 18.55M |
| Capital Expenditures | -1.87M | -767K | -651K | -1.7M | -1.59M | -183K | -399K | -2.02M | -1.38M | -1.69M | -1.66M | -6.51M |
| CapEx % of Revenue | 44.37% | 27.58% | 5.1% | 7.31% | 1.87% | 0.3% | 4.33% | 43.07% | 130.08% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.99K | 0 | 62K |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 38.79M | 0 | 0 | 0 | 38.15M | 0 | 0 | 15.99K | 0 | 0 |
| Cash from Financing | 328.33M | 29.62M | 348K | 365K | 14K | 608K | 15K | 98.02M | 246K | 25.17M | 1.1M | 1.2M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 328.33M | 29.62M | 0 | 365K | 14K | -47M | 0 | 98.02M | 246K | 25.17M | 1.1M | 1.2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 348K | 0 | 0 | 47.61M | 15K | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.98M | -78.46M | 138.91M | -9.03M | -145.72M | 98.63M | 16.77M | 9.1M | -28.35M | 69.05M | 12.03M | -5.78M |
| Free Cash Flow | -39.24M | -43.78M | 99.78M | -36.41M | -47.08M | 128.74M | -21.39M | -29.79M | -39.55M | 27.95M | -26.36M | -31.77M |
| FCF Margin % | -932% | -1574.29% | 781.46% | -157% | -55.43% | 212.28% | -232.13% | -634.48% | -3717.01% | - | - | - |
| FCF Growth % | 16.66% | -134.01% | 566.4% | -22.24% | -19.04% | 360.69% | 18.86% | 6.25% | -21.36% | 189.48% | -19.75% | -37.82% |
| FCF per Share | -0.60 | -0.67 | 1.21 | -0.44 | -0.57 | 2.10 | -0.26 | -0.42 | -0.66 | 0.49 | -0.53 | -0.64 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.93x | -3.71x | 2.82x | -0.97x | 9.59x | 0.88x | 0.92x | 1.19x | -0.89x | 0.71x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |